Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WP-CLDN18.2-CAR-T
- Development stage
- Preclinical
- Lead developer
- Waypoint Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
WP-CLDN18.2-CAR-T is an autologous, ex vivo chimeric antigen receptor (CAR) T-cell therapy developed by Waypoint Bio. It is designed to target Claudin 18.2 (CLDN18.2), a tight junction protein that is highly expressed in several solid tumors, including gastric, gastroesophageal (GE) junction, and pancreatic cancers, while maintaining restricted expression in healthy tissues. The therapy involves engineering a patient's own T cells to express a CAR specific to CLDN18.2, enabling the immune system to selectively identify and eliminate tumor cells. Currently in the preclinical stage, this asset leverages Waypoint Bio's proprietary platform to optimize the design and function of the CAR-T cells for improved efficacy and persistence within the solid tumor microenvironment.
- Other names
- WP-CLDN18.2-CAR-T (ex vivo autologous)
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on WP-CLDN18.2-CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WP-CLDN18.2-CAR-T.